Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...